Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.

Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D.

Am J Clin Oncol. 2009 Apr;32(2):115-21. doi: 10.1097/COC.0b013e318180baa3.

PMID:
19307945
[PubMed - indexed for MEDLINE]
2.

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; Cancer, Leukemia Group B, Chicago, IL.

J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657.

PMID:
20686428
[PubMed - indexed for MEDLINE]
3.

Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA.

J Thorac Oncol. 2008 Mar;3(3):250-7. doi: 10.1097/JTO.0b013e3181653cf4.

PMID:
18317067
[PubMed - indexed for MEDLINE]
4.

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.

Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J, Oaks T, Miller AA, Blackstock AW.

J Thorac Oncol. 2010 Jan;5(1):69-74. doi: 10.1097/JTO.0b013e3181c59a0e.

PMID:
20035186
[PubMed - indexed for MEDLINE]
5.

[Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].

Wang J, Pang QS, Wang P, Wang J, Wang W.

Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):769-72. Chinese.

PMID:
18396691
[PubMed - indexed for MEDLINE]
6.

High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.

Sharp H, Morris JC, Van Waes C, Gius D, Cooley-Zgela T, Singh AK.

Am J Clin Oncol. 2008 Dec;31(6):557-60. doi: 10.1097/COC.0b013e318172d5de.

PMID:
19060587
[PubMed - indexed for MEDLINE]
7.

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.

Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, Miner T, Martel D, Cioffi W, Remis M, Kennedy T, Safran H.

Am J Clin Oncol. 2005 Dec;28(6):570-5.

PMID:
16317266
[PubMed - indexed for MEDLINE]
8.

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.

Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR.

J Thorac Oncol. 2009 Dec;4(12):1466-72. doi: 10.1097/JTO.0b013e3181bbf239.

PMID:
19884861
[PubMed - indexed for MEDLINE]
9.

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC.

Lung Cancer. 2013 Mar;79(3):270-5. doi: 10.1016/j.lungcan.2012.11.017. Epub 2012 Dec 20.

PMID:
23261229
[PubMed - indexed for MEDLINE]
10.

Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.

Kong L, Zhang YW, Hu CS, Guo Y.

Chin J Cancer. 2010 May;29(5):551-5.

PMID:
20426907
[PubMed - indexed for MEDLINE]
Free Article
11.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):785-94.

PMID:
14990633
[PubMed - indexed for MEDLINE]
Free Article
12.

Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.

Boldrini L, Alì G, Gisfredi S, Ursino S, Baldini E, Melfi F, Lucchi M, Comin CE, Maddau C, Tibaldi C, Camacci T, Servadio A, Mussi A, Fontanini G.

Oncol Rep. 2009 Oct;22(4):683-91.

PMID:
19724844
[PubMed - indexed for MEDLINE]
13.

A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.

Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S.

J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):152-8. doi: 10.1007/s00534-011-0400-y.

PMID:
21647560
[PubMed - indexed for MEDLINE]
14.

[Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].

Wang WH, Bao Y, Chen M, Zhang L, Li KX, Xu GC, Deng XW, Lu TX, Cui NJ.

Ai Zheng. 2006 Oct;25(10):1279-83. Chinese.

PMID:
17059776
[PubMed - indexed for MEDLINE]
15.

Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.

Maurel J, Martin-Richard M, Conill C, Sánchez M, Petriz L, Ginès A, Miquel R, Gallego R, Cajal R, Ayuso C, Navarro S, Marmol M, Nadal C, Augé JM, Fernández-Cruz L, Gascón P.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1391-8. Epub 2006 Sep 11.

PMID:
16965868
[PubMed - indexed for MEDLINE]
16.

Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.

Chen Z, Duldulao MP, Li W, Lee W, Kim J, Garcia-Aguilar J.

J Am Coll Surg. 2011 Jun;212(6):1008-1017.e1. doi: 10.1016/j.jamcollsurg.2011.02.024. Epub 2011 Mar 31.

PMID:
21458303
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.

Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C.

Am J Clin Oncol. 2008 Aug;31(4):329-34. doi: 10.1097/COC.0b013e318161dc04.

PMID:
18845990
[PubMed - indexed for MEDLINE]
18.

Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.

Hainsworth JD, Spigel DR, Burris HA 3rd, Markus TM, Shipley D, Kuzur M, Lunin S, Greco FA.

Cancer. 2009 May 15;115(10):2138-46. doi: 10.1002/cncr.24265.

PMID:
19288572
[PubMed - indexed for MEDLINE]
Free Article
19.

Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

Okamoto I, Takahashi T, Okamoto H, Nakagawa K, Watanabe K, Nakamatsu K, Nishimura Y, Fukuoka M, Yamamoto N.

Lung Cancer. 2011 May;72(2):199-204. doi: 10.1016/j.lungcan.2010.08.016. Epub 2010 Sep 9.

PMID:
20828860
[PubMed - indexed for MEDLINE]
20.

Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.

Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H.

Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):53-7.

PMID:
10210540
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk